BioLight Begins Trading on OTCQX®

BioLight has chosen to have its American Depositary Receipts (ADRs) trade on OTCQX®.

BioLight ADRs, where each ADR represents 100 ordinary shares, begin trading today under the symbol “BLGTY” on OTCQX International, a segment of the OTCQX marketplace reserved for high-quality non-U.S. companies that are listed on a qualified international …

Continue reading

DiagnosTear Starts Clinical Study

BioLight announced that DiagnosTear Ltd. has received all necessary approvals from Sheba Medical Center near Tel Aviv to begin a clinical study with its TeaRx, point-of-care Dry Eye Syndrome diagnostic assay.

The purpose of the study is to validate the effectiveness of the test methods developed by DiagnosTear in the tears …

Continue reading

Micromedic Reports Success in Pilot in China

Micromedic reported positive results from a post marketing pilot study conducted in a central hospital in Beijing using the CellDetect™ product for the detection and identification of cervical cancer. The Company also announced receipt of an order for the purchase of 100,000 cervical cancer detection kits from its strategic partner …

Continue reading

BioLight ADRs to Begin Trading on the OTC Exchange

BioLight announced today that it has received approval from the U.S. Securities and Exchange Commission (SEC) to commence its American Depository Receipt (ADR) program.

Over-the-counter (OTC) trading in the BioLight ADR Level 1 will commence on January 22 under the ticker symbol “BLGTY” (CUSIP Number: 09072W103).

Each ADR will be …

Continue reading